China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

by · The Markets Daily

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 4,613,535 shares, a growth of 20,385.5% from the July 15th total of 22,521 shares. Based on an average daily trading volume, of 121,753,983 shares, the short-interest ratio is presently 0.0 days. Currently, 12.6% of the shares of the company are sold short.

China SXT Pharmaceuticals Stock Down 2.2%

NASDAQ SXTC traded down $0.08 during trading hours on Tuesday, hitting $3.51. The company had a trading volume of 246,186 shares, compared to its average volume of 199,997. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $83,758.80. The firm has a 50 day simple moving average of $135.26 and a 200 day simple moving average of $196.54.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share for the quarter. The firm had revenue of $0.26 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Our Latest Analysis on China SXT Pharmaceuticals

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals during the 4th quarter worth approximately $36,000. Virtu Financial LLC lifted its stake in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals in the 3rd quarter valued at $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.

See Also